ML-20 Outcome of high-dose methotrexate-based chemotherapy with or without Rituximab for primary central nervous system lymphoma

High-dose methotrexate based chemotherapy(HD-MTX) improved outcome of primary central nervous system lymphoma(PCNSL), but the prognosis is still poor. Recent studies showing that Rituximab is very effective for systemic lymphoma, the role of Rituximab for PCNSL is unclear. 34 patients diagnosed PCNS...

Descripción completa

Detalles Bibliográficos
Autores principales: Takezaki, Tatsuya, Ota, Kazutaka, Kuroda, Junichiro, Shinojima, Naoki, Takeshima, Yuki, Matsuura, Jin, Yamamoto, Takahiro, Makino, Keishi, Mukasa, Akitake
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Supplement Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7699048/
http://dx.doi.org/10.1093/noajnl/vdaa143.077
_version_ 1783615959402020864
author Takezaki, Tatsuya
Ota, Kazutaka
Kuroda, Junichiro
Shinojima, Naoki
Takeshima, Yuki
Matsuura, Jin
Yamamoto, Takahiro
Makino, Keishi
Mukasa, Akitake
author_facet Takezaki, Tatsuya
Ota, Kazutaka
Kuroda, Junichiro
Shinojima, Naoki
Takeshima, Yuki
Matsuura, Jin
Yamamoto, Takahiro
Makino, Keishi
Mukasa, Akitake
author_sort Takezaki, Tatsuya
collection PubMed
description High-dose methotrexate based chemotherapy(HD-MTX) improved outcome of primary central nervous system lymphoma(PCNSL), but the prognosis is still poor. Recent studies showing that Rituximab is very effective for systemic lymphoma, the role of Rituximab for PCNSL is unclear. 34 patients diagnosed PCNSL received HD-MTX chemotherapy adding rituximab. Response rates were 74%(20/27) for newly diagnosed PCNSL patients, 85.7%(6/7) for recurrent PCNSL patients. Major side effects were infusion reaction and respiratory infections disease. We have to compare the outcome of HD-MTX chemotherapy retrospectively.
format Online
Article
Text
id pubmed-7699048
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-76990482020-12-02 ML-20 Outcome of high-dose methotrexate-based chemotherapy with or without Rituximab for primary central nervous system lymphoma Takezaki, Tatsuya Ota, Kazutaka Kuroda, Junichiro Shinojima, Naoki Takeshima, Yuki Matsuura, Jin Yamamoto, Takahiro Makino, Keishi Mukasa, Akitake Neurooncol Adv Supplement Abstracts High-dose methotrexate based chemotherapy(HD-MTX) improved outcome of primary central nervous system lymphoma(PCNSL), but the prognosis is still poor. Recent studies showing that Rituximab is very effective for systemic lymphoma, the role of Rituximab for PCNSL is unclear. 34 patients diagnosed PCNSL received HD-MTX chemotherapy adding rituximab. Response rates were 74%(20/27) for newly diagnosed PCNSL patients, 85.7%(6/7) for recurrent PCNSL patients. Major side effects were infusion reaction and respiratory infections disease. We have to compare the outcome of HD-MTX chemotherapy retrospectively. Oxford University Press 2020-11-28 /pmc/articles/PMC7699048/ http://dx.doi.org/10.1093/noajnl/vdaa143.077 Text en © The Author(s) 2020. Published by Oxford University Press, the Society for Neuro-Oncology and the European Association of Neuro-Oncology. http://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Supplement Abstracts
Takezaki, Tatsuya
Ota, Kazutaka
Kuroda, Junichiro
Shinojima, Naoki
Takeshima, Yuki
Matsuura, Jin
Yamamoto, Takahiro
Makino, Keishi
Mukasa, Akitake
ML-20 Outcome of high-dose methotrexate-based chemotherapy with or without Rituximab for primary central nervous system lymphoma
title ML-20 Outcome of high-dose methotrexate-based chemotherapy with or without Rituximab for primary central nervous system lymphoma
title_full ML-20 Outcome of high-dose methotrexate-based chemotherapy with or without Rituximab for primary central nervous system lymphoma
title_fullStr ML-20 Outcome of high-dose methotrexate-based chemotherapy with or without Rituximab for primary central nervous system lymphoma
title_full_unstemmed ML-20 Outcome of high-dose methotrexate-based chemotherapy with or without Rituximab for primary central nervous system lymphoma
title_short ML-20 Outcome of high-dose methotrexate-based chemotherapy with or without Rituximab for primary central nervous system lymphoma
title_sort ml-20 outcome of high-dose methotrexate-based chemotherapy with or without rituximab for primary central nervous system lymphoma
topic Supplement Abstracts
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7699048/
http://dx.doi.org/10.1093/noajnl/vdaa143.077
work_keys_str_mv AT takezakitatsuya ml20outcomeofhighdosemethotrexatebasedchemotherapywithorwithoutrituximabforprimarycentralnervoussystemlymphoma
AT otakazutaka ml20outcomeofhighdosemethotrexatebasedchemotherapywithorwithoutrituximabforprimarycentralnervoussystemlymphoma
AT kurodajunichiro ml20outcomeofhighdosemethotrexatebasedchemotherapywithorwithoutrituximabforprimarycentralnervoussystemlymphoma
AT shinojimanaoki ml20outcomeofhighdosemethotrexatebasedchemotherapywithorwithoutrituximabforprimarycentralnervoussystemlymphoma
AT takeshimayuki ml20outcomeofhighdosemethotrexatebasedchemotherapywithorwithoutrituximabforprimarycentralnervoussystemlymphoma
AT matsuurajin ml20outcomeofhighdosemethotrexatebasedchemotherapywithorwithoutrituximabforprimarycentralnervoussystemlymphoma
AT yamamototakahiro ml20outcomeofhighdosemethotrexatebasedchemotherapywithorwithoutrituximabforprimarycentralnervoussystemlymphoma
AT makinokeishi ml20outcomeofhighdosemethotrexatebasedchemotherapywithorwithoutrituximabforprimarycentralnervoussystemlymphoma
AT mukasaakitake ml20outcomeofhighdosemethotrexatebasedchemotherapywithorwithoutrituximabforprimarycentralnervoussystemlymphoma

Ejemplares similares